With the lead line of “There is more to my acromegaly than just numbers on a page” comes a new informational website from the Chiesi Global Rare Diseases patient support group. Rethink Acromegaly is a
From the desk of Jorge D. Faccinetti – chief editor and co-founder – I am thrilled to announce that Pituitary World News co-founder Dr. Lewis Blevins has been working on a new book on Cushing’s
Prolactinomas in men tend to be large tumors and are often invasive.
From the desk of Dr. Lewis Blevins comes a review of three important studies on Cushing’s Syndrome: Paediatric Cushing syndrome: a prospective, multisite, observational cohort study – The authors of this study report the largest
SAN FRANCISCO, MARCH 22, 2024 – We are very pleased to announce that Pituitary World News co-founder Lewis S. Blevins Jr. M.D. has received the 2024 AACE Excellence in Humanities Award from the American Association
From the desk of Dr.Lewis S. Blevins, Jr. – co founder – With most endocrinologic conditions, physicians prescribe medication, patients take it with varying degrees of compliance, laboratory test are obtained to assess degree of
Reading about each of these famous giants prompted me to dig a bit more to see if there was anything new to report on the genetics of pituitary adenomas. Here’s the latest.
Today’s podcast is about our super athlete friend Risa August and her new book about her acromegaly experience, her life, and her 1,800 mile ride from Canada to Mexico.
Spain and Spanish-speaking countries have been our focus as we seek to develop more content in Spanish for our edition of Pituitary Word News in Español. Today’s podcasts covers part of the conference and shares my conversations with three world-renowned Spanish endocrinologists.
Pituitary Grand Rounds is a new PWN program loosely based on the practice medical schools routinely use to educate young doctors. It is a fantastic way to share patient’s insights, their symptoms and signs, how
In today’s podcast, we talk with Giacomo Chiesi, Head of Global Rare Diseases at the Chiesi Group, where he leads a team in developing and marketing treatments for rare and ultra-rare diseases.